bioRxiv Science⌕ Search

bioRxiv · 10.1101/2025.03.04.641374

Potential Systemic Availability Classification of Chemicals for Safety Assessment

Abstract

The assessment of chemical safety is essential for protecting human health, yet current approaches have severe limitations. They are unable to address the rapidly growing number of substances requiring evaluation and further rely on animal testing, which the public expects to be phased out for ethical reasons. To address this, the European Partnership for Alternative Approaches to Animal Testing (EPAA) proposed the use of a novel framework for the classification of systemic toxicity based on new approach methodologies. One dimension of this framework is the grouping of substances into different classes of Potential Systemic Availability (PSA) concern (low, medium, high). But so far it remained conceptually and practically unclear how this classification can be achieved. Here, we outline the theoretical considerations for a health-protective definition of PSA concern classes and present a method for the quantitative evaluation of this property. Using high-throughput physiologically based kinetic modelling, we are able to classify the PSA concerns of 139 out of 150 EPAA NAM Designathon compounds. Further, we manually annotate these compounds to evaluate the plausibility of predicted classifications against expert judgement. Our results outline under which circumstances it is appropriate to prioritise or deprioritise chemicals due to their toxicokinetic properties. However, we find that most compounds cannot be assessed on their PSA alone and need to be considered medium PSA concern so that classification into any overall systemic toxicity concern class remains possible. Future integration of bioactivity data will be necessary to fully judge the utility of our method and of the entire framework.

Source connections

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Geci, R., Paini, A., Worth, A. P., Kuepfer, L., Schaller, S.. 2025-03-05. Potential Systemic Availability Classification of Chemicals for Safety Assessment. https://doi.org/10.1101/2025.03.04.641374

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

Lipid-ASO therapeutics exhibit differential tissue targeted delivery upon systemic or local CNS administration

Antisense oligonucleotides (ASOs) are a powerful therapeutic modality, but their full potential is hindered by pharmacokinetic properties that affect tissue and cellular delivery. Lipid conjugation is increasingly used to modulate ASO's biodistribution and promote extrahepatic activity, yet lipid dependent effects on in vivo functional delivery, particularly in the central nervous system (CNS), remain less explored. Here, we performed a side by side in vivo comparison of cholesterol, palmitic acid (C16:0), docosanoic acid (C22:0), and eicosapentaenoic acid (C20:5) conjugated to a fully phosphorothioated 3 10 3 LNA gapmer ASO targeting the Malat1 long non coding RNA. Lipid-ASO conjugates were administered systemically or locally in the brain of mice and evaluated for tissue level and cellular level distribution by imaging, qPCR and single-cell RNA sequencing, simultaneously annotating cell origin and global transcriptional changes within the cell. Following systemic administration in mice, lipid conjugation improved overall multi organ efficacy compared to unconjugated ASO, but with pronounced tissue specific differences. Single cell sequencing of liver and heart transcriptomes revealed lipid dependent cellular uptake patterns and transcriptional responses distinct from administration of unconjugated ASO. After intracerebroventricular administration, selected fatty acid conjugates enhanced silencing in deep brain regions such as the striatum, whereas cholesterol conjugation impaired functional delivery despite increased CNS retention. Light-sheet microscopy showed restricted parenchymal penetration of cholesterol ASOs compared with broader but heterogeneous distribution of palmitic acid conjugate. Together, these findings demonstrate that lipid identity critically determines ASO efficacy, productive cellular uptake, and regional CNS engagement, emphasizing the need for context specific lipid design in ASO therapeutic development.

pharmacology and toxicology↗

Novel Dissymmetric Ionizable Lipid-Assembled Lipid Nanoparticles for Delivery of Ferroptosis-Related siRNA in Diabetic Treatment

Small interfering RNA (siRNA) enables precise post-transcriptional gene silencing for refractory diseases, yet its clinical translation remains limited by the lack of safe and efficient delivery vectors. Inspired by the dissymmetric alkyl chain architecture of natural membrane phospholipids, we designed and synthesized 34 novel ionizable lipids with dissymmetric hydrophobic tails and formulated them into lipid nanoparticles (LNPs). Through systematic physicochemical and biological assessments, we established clear structure-activity relationships and identified two lead LNPs (O14-LNP, H18a-LNP) with superior endosomal escape capacity, enhanced in vivo gene silencing potency, and favorable biosafety relative to the clinical benchmark MC3-LNP. In both streptozotocin-induced and spontaneous db/db type 2 diabetes (T2D) mouse models, lead LNPs delivering ferroptosis-related siRNAs effectively ameliorated glucose and lipid metabolic disorders, restored islet function, and alleviated hepatic steatosis. This study not only lays a theoretical foundation for the rational design of novel ionizable lipids, but also validates the therapeutic potential of siRNA therapy targeting ferroptosis, providing a versatile delivery platform and targeted therapeutic strategy for the treatment of T2D.

pharmacology and toxicology↗

A Dual-Action Mechanism to Prevent OX40 Signaling: The Structural Basis for the Differentiated Antagonist STAR-0310

Atopic dermatitis (AD) is a chronic inflammatory disease sustained by dysregulated T cell activity. The OX40/OX40L pathway drives effector and memory T cell proliferation, survival, and cytokine production, making it a key therapeutic target. STAR-0310, a novel anti-OX40 antibody, binds a noncanonical epitope that sterically blocks receptor trimerization without inducing agonism. Structural and functional studies demonstrated a dual mechanism: prevention of new OX40/OX40L interactions and efficient disruption of pre-formed complexes, outperforming comparator antibodies. The pure antagonism and complex disruption capacity of STAR-0310 support its clinical evaluation (NCT06782477) as a differentiated OX40-targeted therapy for AD. HighlightsO_LINovel binding mechanism: STAR-0310 engages OX40 distal to the OX40L site, sterically blocking receptor trimerization without inducing agonism. C_LIO_LIDual action: Prevents formation of new OX40/OX40L complexes and efficiently disrupts pre-formed complexes sustaining inflammation. C_LIO_LIDifferentiation from competitors: Achieves greater efficiency in complex disruption compared with rocatinlimab and IMG-007 with no partial agonist activity. C_LIO_LIClinical potential: Pure antagonist profile supports ongoing evaluation of STAR-0310 (NCT06782477) as a best-in-class OX40 therapy for atopic dermatitis. C_LI

pharmacology and toxicology↗